CardiaCures is reinventing personalized medicine for heart disease.

We are developing software-linked cardiovascular medicines designed to deliver the right therapy, at the right dose, for the right patient by design. Powered by the Translational Cures platform, our approach combines model-informed precision dosing, dosing software intended to be integrated into the FDA-approved drug label, and a drug-development pathway built for medicines where patient variability, narrow therapeutic windows, and monitorable biomarkers matter most.

Our first focus is arrhythmia. Effective antiarrhythmic drugs exist, but many are limited by dosing complexity, safety concerns, QT monitoring requirements, and the burden of hospital initiation. CardiaCures is building a multi-drug pipeline for atrial fibrillation, with a go-to-market path in inherited arrhythmia, to help more patients safely and reliably reach the therapeutic window.

CardiaCures is creating a new model for cardiac care: software-linked drugs developed, submitted, commercialized, and reimbursed as drugs. Our goal is to enable smaller, faster clinical trials, reduce safety failures, and bring precision-dosed cardiovascular therapies to patients who need better options.

Contact us to learn more about our pipeline, partnership opportunities, and our mission to reinvent personalized medicine for heart disease.


CardiaCures

Org chart

Teams

Offices

CardiaCures

Org chart

Teams

Offices

Related companies